Table 2.
Demographics of patients undergoing transcatheter mitral valve implantation.
| Patient number | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 |
|---|---|---|---|---|---|---|
| Age/Sex | 75/F | 77/F | 72/F | 66/M | 66/F | 64/F |
| Medical history | HT, AF, chole-cystectomy | HT, CHD, AF |
HT, PHD | CHD, renal failure | Biological mitral valve degeneration | HT, diabetes |
| Previous heart operation (year) |
MVR (9) |
MVR (12) |
MVR (11) |
MVR+ CABG (11) |
MVR+ TVR (6) |
MVR+ pacemaker implanted (5) |
| Type of degenerated surgical bioprosthesis (Size) | Regent TM MHPJ-505 (29 mm) | Hall TM M7700 (27 mm) |
Hall TM M7700 (27 mm) | Hall TM M7700 (27 mm) |
Regent TM MHPJ-505 (29 mm) | Regent TM MEHPJ-505 (27 mm) |
| Current valve status | MR | MR, TR | MR | MR | MR, TR | MR |
| NYHA functional class | III | III | III | IV | III | IV |
| STS score (%) | 5.110 | 7.415 | 6.063 | 14.842 | 6.921 | 12.166 |
AF, atrial fibrillation; CABG, coronary artery bypass grafting; CHD, coronary heart disease; HT, hypertension; MVR, mitral valve replacement; PHD, pulmonary hypertension; STS, The Society of Thoracic Surgeons; MR, mitral regurgitation; TR, tricuspid regurgitation; Regent TM: St. Jude Medical Inc., Saint Paul, Minnesota, USA; Hall TM: Medtronic Inc., Minneapolis, Minnesota, USA.